COL-3 benefits patients with AIDS-related Kaposi's sarcoma.
Furlow
Bryant
B
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D012514:Sarcoma, Kaposi / Q000150:complications / Q000188:drug therapy*; D013754:Tetracyclines / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D061965:Matrix Metalloproteinase Inhibitors; D013754:Tetracyclines; C117155:tetracycline CMT-3